Introduction Andy Vail, RDS NW Associate Director Programme Part - - PowerPoint PPT Presentation

Introduction

Andy Vail, RDS NW Associate Director

Programme

Part I: Morning session - 10.00 am to 12.30 pm

10.00 am Introduction 10.10 am How the Research Design Service can help you 10.20 am Importance of Patient and Public Involvement 10.30 am Introduction to NIHR funding programmes (video) 10.50 am Questions – please use the chat facility 11.10 am Break 11.20 am The Supporting Network – Clinical Research Network (CRN) and Clinical Trials Units (CTU) 11.45 am The i4i funding programme 11.55 am Questions – please use the chat facility 12.10 pm End of morning session – stories from successful applicants (videos)

Programme

Part II: Virtual Marketplace - 1.30 pm to 3.30 pm For those who have signed up.

The Research Design Service

Thomas Allen, RDS NW Adviser

@NIHR_RDSNW

Research Design Service North West

Provides advice on research design to researchers to develop high quality research proposals for national, peer-reviewed funding competitions for applied health or social care research.

Example of funders where we can advise

• National Institute for Health Research.
• Medical Research Council.
• Economic and Social Research Council.
• Charities.

Funding needs to be national and peer reviewed. Research needs to be in applied health or social care.

Our expertise

• Methodology including but not limited to:
• quantitative, including statistical
• qualitative
• mixed methods
• health economics
• health psychology and behaviour change
• specialist methodologies.
• Specific funding programme application advice.

See www.rds-nw.nihr.ac.uk/about-us/expertise-a-z for more examples

We can also help with

• Identifying appropriate funding.
• Finding collaborators and building an appropriate team.
• Involving the public.
• Formulating the research question.
• “Grantsmanship.”
• Signposting to specialised support.
• Ethical and governance issues.
• Getting the narrative right.
• A critical read of your proposal.
• And much more.

Some of the other things we do

• Developing Funding Proposals in Applied Health and

Social Care events.

• Pre-submission panels, three a year - open to clients.
• Newsletters - see resources and events on website.
• E-bulletin.
• Videos.
• Self-help resources.

Find all our resources at - www.rds-nw.nihr.ac.uk Sign-up for information and news - www.rds-nw.nihr.ac.uk/about-us/rds-nw-mailing-list

What happens when you contact us

Complete an advice request form Case manager will provide advice and/or other advisers will provide advice Depending on your requirements, you will be advised face-to-face via email, video conference or telephone. If eligible you will be allocated a case manager and/or you will be signposted to other sources of help

What we cover in your initial advice meeting

Depending on your needs we may cover:

• expectations
• importance of the question
• existing research / literature review
• potential funding streams
• study design
• feasibility of recruitment strategy
• track record of team
• Public Involvement.

RDS clients

“Support from the RDS has been invaluable in guiding us through the complexities of the application process. The blend of structured meetings and one-to-one support was very helpful. The team also had excellent contacts with relevant expertise that could support our proposal.” Consultant Clinical Psychologist

Hear from our clients at www.rds-nw.nihr.ac.uk/our-clients

How to access the service

01524 593209

@

rds.nw@nihr.ac.uk

WWW

www.rds-nw.nihr.ac.uk/request-advice @NIHR_RDSNW

Public Involvement including the Public Involvement Fund

Suzanne Parsons, RDS NW Specialist Public Involvement Adviser

About Public Involvement

• Research being carried out ‘with’ or ‘by’ members of the public rather

than ‘to’, ‘about’ or ‘for’ them

• Patients, potential patients, carers and people who use health and social

care services

• Offering advice as members of a study’s steering group, identifying

research priorities, commenting on and developing research materials, co-applicant on bid, undertaking interviews with research participants etc What it’s not:

• Recruitment of people as research participants

Context - NIHR and Public Involvement

• NIHR ‘Going the Extra Mile’ 2015 -

2025

• UK Public Involvement Standards –

developed by Chief Scientist Office (Scotland), Health and Care Research Wales, the Public Health Agency (NI) and the NIHR (England) “Our vision is for a population actively involved in and engaged with research to improve health and wellbeing for themselves, their family and communities” (NIHR Going the Extra Mile)

Public Involvement and Your NIHR Application

• Patient and public involvement plans assessed by funding committee

including patient and public members

• Consideration of public involvement necessary both for stage 1 and 2

Applications should demonstrate evidence of:

• Public involvement in developing the research application
• Public involvement plans as part of the research

How RDS NW can help – support for public involvement

• Advisers/case managers – public involvement advice
• Specialist Advisers - for extra help with complex issues
• Public contributors on ‘mock’ panels
• Resources on RDS NW webpage
• RDS NW public involvement fund scheme

https://www.rds-nw.nihr.ac.uk/public-involvement/

The Public Involvement Fund

• In receipt of advice from RDS North West
• Developing proposal for national, peer-reviewed open call funding

competitions for applied health or social care research

• At any stage prior to final submission
• In region of £350 per project
• Light touch application process but needs to include clear plan about the

planned public involvement activity

What does it cover?

• Setting up meetings with groups (e.g. venue, providing refreshments)
• Zoom subscription
• Reimburse patients, carers etc. for their time (e.g. thank you voucher)
• Fees for a public collaborator (e.g. involve in writing grant)
• Out-of-pocket expenses (e.g. travel, subsistence, carer costs)
• Not to be used for the research itself

https://www.rds-nw.nihr.ac.uk/public-involvement/fund/

Summary

 Can you demonstrate sufficient public involvement in the development of the application? If not, consider applying to public involvement fund  What plans are in place for public involvement during the research?  Has a budget been included for public involvement during the research?  Is your plan English summary understandable?

Targeting the right funding stream

Professor Soo Downe, Senior Methods Lead

NIHR funding programmes overview

Broad research area EME HS&DR HTA i4i PGfAR PDG PHR PRP RfPB SR Public health Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Health services and organisation No Yes Yes No Yes Yes No Yes Yes Yes Clinical evaluation and translation Yes No Yes Yes Yes Yes No Yes Yes Yes Technology development No No No Yes No No No Yes No No Social care Yes Yes Yes No Yes Yes Yes Yes Yes Yes Types of evidence EME HS&DR HTA i4i PGfAR PDG PHR PRP RfPB SR Evidence synthesis No Yes Yes No Yes Yes Yes Yes Yes Yes Evidence generation Yes Yes Yes Yes Yes Yes Yes Yes Yes No Programmes

• f research

No Yes No No Yes Yes Yes Yes No Yes

Funding calls, amounts and length

EME HS&DR HTA i4i PGfAR PDG PHR PRP RfPB SR Calls and competitions (number of opportunities to apply per year) Researcher-led 3 3 3 3 3 3 3* N/A 3 1* Commissioned 3 3 3 1* N/A N/A 3* 3* N/A N/A Themed Frequency as advertised EME HS&DR HTA i4i PGfAR PDG PHR PRP RfPB SR Funding amounts and periods Funding limit** No limit No limit No limit No limit No limit*** £100k No limit No limit**** £350k £400k## Period of funding No fixed period No fixed period No fixed period Up to 3 years# No fixed period*** 0-18 months No fixed period No fixed period**** Up to 3 years Up to 3 years

* Subject to change. ** Applicants must fully justify all costs. *** Period and level of funding depends on nature of proposed work, in particular whether a fully powered evaluative is included – funding above £2.5 million will be unusual. Programmes terminating in feasibility studies will be unlikely to receive more than £500,000. **** Period and level of funding depends on the requirements of the research specification. # For i4i Connect, the funding limit is £150,000 and the maximum duration is 12 months. For Challenge, the maximum duration is five years. ## Researcher-led period is 9-12 months with funding limit of £5000. Commissioned-led is every 3 years with a funding limit of £400,000.

Funding Streams

Commissioned work stream Designed to meet the needs of decision makers, typically but not exclusively within NHS. Researcher-led work stream Calls for applications on research topics/questions directly proposed by researchers. Theme calls Calls in priority areas e.g. Injuries, accidents and urgent and emergency care – see www.nihr.ac.uk/explore-nihr/funding- programmes/themed-calls.htm

MRC-NIHR Efficacy and Mechanism Evaluation (EME)

This Programme primarily supports clinical trials, and other robustly designed studies that test the efficacy of interventions. The Programme looks to attract studies with novel methodological designs that deliver results more efficiently, reduce the study timeline, and maximise the knowledge gained.

www.nihr.ac.uk/eme

NIHR Health Technology Assessment (HTA)

This programme supports research that is immediately useful to patients, clinical practice, and policy or decision makers.

www.nihr.ac.uk/hta

NIHR Health Services & Delivery Research (HS&DR)

This programme funds research to produce evidence to impact on the quality, accessibility and organisation of health and social care

• services. This includes evaluations of how the NHS and social care

might improve delivery of services.

www.nihr.ac.uk/hsdr

NIHR Public Health Research (PHR)

The primary aim of the programme is the evaluation of practical

• interventions. They fund both primary research, mainly evaluative but

also some preparatory research, and secondary research i.e. evidence synthesis.

www.nihr.ac.uk/phr

NIHR Invention for Innovation (i4i)

The aim of this programme is to de-risk early stage projects that have a strong potential for commercialisation and acceptance for use in the NHS, making them attractive to follow-on funders and investors. i4i funds collaborative research projects that have demonstrated proof-of-principle and have a clear pathway towards adoption and commercialisation.

www.nihr.ac.uk/i4i

NIHR Research for Patient Benefit (RfPB)

This programme supports research that is concerned with the day- to-day practice of health service staff. Research proposals should have a clear trajectory towards benefiting the health or wellbeing of patients and users of the NHS.

www.nihr.ac.uk/rfpb

NIHR Research for Social Care (RfSC)

Research for Patient Benefit is now running a dedicated social care funding call every year, starting September 2019. This is an annual call for social care research proposals.

www.nihr.ac.uk/documents/nihr-research-for-social-care-rfsc-call-specification/21740

NIHR Programme Grants for Applied Research (PGfAR)

The aim of this funding programme is to deliver research findings that will lead to clear and identifiable patient benefits, typically through promotion of health, prevention of ill health, and optimal disease management, including safety and quality.

www.nihr.ac.uk/pgfar

NIHR Programme Development Grants (PDG)

This funding programme is designed to position and equip a research team in submitting a competitive research proposal to PGfAR in the future.

www.nihr.ac.uk/pdg

NIHR Policy Research Programme (PRP)

This programme funds high quality research to deliver robust, relevant, timely, accessible and intelligible evidence to government and arms-length bodies.

www.nihr.ac.uk/prp

NIHR Systematic Reviews (SR)

Systematic reviews identify, evaluate, combine and summarise the findings of all relevant individual studies, to provide decision makers with the best possible information about the effects of tests, treatments and other interventions used in health and social care.

www.nihr.ac.uk/sr

Dace Dimza-Jones Industry Facilitator

Why choose Greater Manchester?

(...because Manchester “CAN” and delivers today, “what the world does tomorrow”)

Patient at the heart of research

Dayle Roberts Assistant Research Delivery Manager

NIHR Clinical Research Network (CRN)

Our mission: Supporting research to make patients, and the NHS, better

Greater Manchester CRN provides unique opportunities to engage in ground-breaking research studies,

to innovate, shape and create the best possible healthcare for the current and future generations of Greater Manchester and increase the wealth of population.

Facilitate research delivery within the NHS and non-NHS settings

Non-NHS settings

Schools Care homes Hospices Prisons

Academic studies Commercial studies

Support

15 Local Clinical Research Networks

Green Domain

Delivering research across 30 clinical specialties

Infectious diseases & microbiology Injuries & emergencies Mental Health Metabolic & endocrine disorders Musculoskeletal disorders Neurological disorders Ophthalmology Oral & dental heath Primary Care Public Health Renal Disorders Reproductive health & childbirth Respiratory disorders Stroke Surgery Ageing

Anaesthesia, Perioperative Medicine & Pain Management

Cancer Cardiovascular disease Children Critical Care Dementias & neurodegeneration Dermatology Diabetes Ear, nose & Throat Gastroenterology Genetics Haematology Health Services & delivery research Hepatology

Primarily funded by the Department

• f Health and Social Care, but also

receive UK Aid funding to support research for people in low- and middle-income countries. Nation's largest funder of health and care research Provides the people, facilities and technology that enables research to thrive Works in partnership with the NHS, universities, local government, other research funders, patients and the public, delivering and enabling world- class research that transforms people's lives, promotes economic growth and advances science.

Coordinating Centre

Manages the CRN

• n behalf of the

Department of Health and Social Care.

Time and Target

Deliver NIHR CRN Portfolio studies to recruitment target within the planned recruitment period

NIHR CRN HLOs 2020/21

Participant Recruitment

Deliver significant levels

• f participation

in NIHR CRN Portfolio studies

New Commercial Studies

Increase the number of studies delivered for the commercial sector with support from the NIHR Clinical Research Network

Provider Participation

Widen participation in research by enabling the involvement of a range of health and social care providers

Dementia and Neurodegeneration Recruitment

Deliver significant levels of participation in NIHR CRN Portfolio Dementias and Neurodegeneration (DeNDRoN) studies

Participant Experience

Demonstrate to people taking part in health and social care research studies that their contribution is valued

Site Set-up

Reduce intra-study site set-up times for NIHR CRN Portfolio studies

Local Specialties

Improve access to research by increasing recruitment in priority specialties (including difficult to reach groups)

We support delivery of research across

Population of almost 3 million

Commercial 28.49% Academic 71.51%

25.1% Median

Help to increase the opportunities for participants to take part in clinical research Ensure that studies are carried out efficiently ( to time and target)

Support the Government’s Strategy for UK Life Sciences by improving the environment for commercial contract clinical research

14 NHS Trusts

11 Clinical Commissioning Groups

More than 500 GP practices and pharmacies

NIHR CRN Greater Manchester

997 Studies

GM LCRN share of English recruitment in FY 2019/20 is 6.9%

10K 20K 30K 40K 50K 60K 70K 80K 90K 100K 10.00K 20.00K 30.00K 40.00K 50.00K 60.00K 70.00K 80.00K 90.00K 100.00K Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar

Recruitment Cumulative Target

Recruitment Cumulative Target

51,455 Recruits

Interventional Observational Both 48 % 44 % 7 %

1st to recruit to Time and Target (Commercial)

PAT-POPS is 3rd highest recruiting study ever

44.501 recruits

One of the most commercially active networks

High number of

1st 1st 1st

Global

Europien UK

Fantastic and dedicated research teams

Global/European/UK 1st NCA/MFT/Christie backbone for early phase studies 4 National Specialty Leads

We work in collaboration with

What value does the Study Support Service offer to researchers across Greater Manchester? Our Study Support Service helps researchers and the life sciences industry plan, set up and deliver high quality research to time and target. We do this through our delivery support framework, encompassing six areas of added value.

Early Contact & Engagement

Commercial feasibility

Competitive Global market

Commercial 28.49% Academic 71.51%

25.1% Median

Company approaches PI/Study team directly PI/Study team decides to carry/not to carry out the study Study successfully

• pened at the site

4

   LCRN send EOI to the suggested PI/Study teams PI/Study team has 5-10 days to respond LCRN returns competed EOIs to NIHR CC

5

  EOIs from across England submitted to Sponsor/CRO Sponsor decides which site will be site selected

6 Study successfully

• pened at site

1

Company approaches NIHR CC

2

Site ID Process EOI forms sent to LCRNs

3

LCRN (Speciality lead) identifies potencial PIs/Sites

Early Feedback

Site Identification

Expression

• f Interest

Expressions of interest

Realistic recruitment targets Specialty lead

   Recommendations Local intelligence Local feasability

Industry Facilitator

10-12 Business Days

3 Business Days 7-9 Business Days 1 Business Day

Optimising planing and delivery

Effective Study Set-Up SIV/SSV

CRN presence at research meetings, SIV/SSVs

Research delivery team

Performance Monitoring

Spot where the support

• r assistance is needed

Business Intelligence

   What does it provide? Trust & Specialty reporting feature Horizon scanning R-Peak data vs CPMS data

Business development

Building bridges to connect personalities and inspire the development of excellent research

• First choice for all UK Studies
• Protocol development
• Research Masterclass
• Significant increase in commercial and Real World Studies
• Collaboration between Primary & Secondary Care
• PERFORMANCE with all types of commercial studies

Business Development

Our experienced team has strong relationships with researchers and the industry. We are present at every step

• f the study and help facilitate

conversation to ensure swift study set up and delivery

Industry team

Dedicated IOM alongside with research facilitators ensure that every study is performance managed and recruit to time &

• target. Team provides ongoing

support & assistance to sponsors and CROs

Communications Patient & Public Involvement

Type something

janet.eastwood@mft.nhs.uk david.pickthall@mft.nhs.uk

     Raise the profile of clinical research Promote the importance of clinical research with local service providers and provide communications expertise to staff/partners Work with local clinicians and patents to develop stories (case studies) Deliver local elements of national campaigns i.e. ‘Be Part of Research’ Events represent the network and help to arrange networking events

    Help you to promote studies Branding, leaflets, materials, social media – events etc. Celebrate success – global firsts Campaigns and Awareness Weeks

How we can help you

FARSITE is a profiling tool for searching, finding, and contacting patients with research opportunities, whilst still preserving their confidentiality

Partnership between NIHR Clinical Research Network Greater Manchester, NorthWest EHealth, Health Innovation Manchester and Salford Royal NHS Foundation Trust

Our aim is to improve recruitment to NIHR Portfolio research studies

researchsupport.crngm@nihr.ac.uk A single point of contact for Business Development, Study Support &Industry. +44 (0)161 701 5600 Call us @NIHRCRN_gman Follow us on Twitter Website More about us here

Ove rvie w o f a Clinic a l T ria ls Unit

Be n Ha rdwic k Supe rvising T ria ls Ma na g e r L ive rpo o l Clinic a l T ria ls Ce ntre Unive rsity o f L ive rpo o l

Wha t a re Clinic a l T ria ls Units

 T

he NI HR pa ne l inc re a sing ly re q ue st CT U suppo rt e ve n fo r fe a sib ility studie s. CT U c o lla b o ra tio n re a ssure s the pa ne l tha t the de sig n a nd de live ry o f the tria l will b e ro b ust a nd o ptimise a c c rua l.

 Spe c ia list units with a spe c ific re mit to de sig n, c o nduc t, a na lyse a nd

pub lish c linic a l tria ls & o the r we ll-de sig ne d studie s

 Pro vide spe c ia list sta tistic a l, e pide mio lo g ic a l, me tho do lo g ic a l

a nd c o o rdina tio n e xpe rt a dvic e ne e de d to unde rta ke suc c e ssful c linic a l tria ls

CT U Ro le s

• Re spo nsib le fo r da y to da y ma na g e me nt o f tria ls. T

ria l c o -o rdina to rs a re the ma in c o nta c t fo r a tria l a nd ke y to the suc c e ssful tria l de live ry.

T ria l ma na g e me nt

• Sta tistic ia ns invo lve d in tria l de sig n, de c isio ns o n prima ry o utc o me , sa mple

size c a lc ula tio ns, c o mple te inte rim a nd fina l a na lyse s in a c c o rda nc e with the Sta tistic a l Ana lysis Pla n. I nput fo c use s o n the pla nning pha se , mo nito ring da ta q ua lity, inte rim a nd fina l a na lyse s.

Sta tistic s

• I

S pro g ra mme rs de ve lo p b e spo ke a pplic a tio ns fo r ra ndo misa tio n a nd da ta c o lle c tio n syste ms a nd a lso tria l we b site s a nd mo b ile a pplic a tio ns

I nfo rma tio n Syste ms

• Da ta Ma na g e rs e nsure tha t a ll ne c e ssa ry da ta is c o lle c te d in a time ly ma nne r.

T he y a re invo lve d in the tria l fro m the pla nning sta g e a nd a re invo lve d in CRF De sig n, Da ta e ntry a nd Da ta Que rying

Da ta Ma na g e me nt

UK CRC Re g iste re d CT Us

• Re g istra tio n a pplic a tio ns

Asse sse d by international

review committee

• Evaluated against specific

key competencies & evaluation criteria

• As of 2019: 53 re g iste re d

CT Us (47 F ull/ 6 pro visio na l)

• NE

T SCC Suppo rt funding fo r Re g iste re d CT Us

• We b site inc lude s a to o l

to se a rc h fo r CT Us

www.ukcrc-ctu.org.uk

CT U Ro le : pre -funding

 Sta tistic s & Me tho do lo g y  F

e a sib ility

 Budg e t  T

ime ly sub missio n to F unde r

 Advic e o n e sta b lishme nt a nd c o nstitutio n o f I

DSMC & T SC

 L

ia iso n with Spo nso r

 T

ria l supplie s

 Links to other expertise (e.g. Health Economics)  Pre -a pplic a tio n c o ntrib utio n no t c o ste d to g ra nt Po st a wa rd c o ntrib utio n c o sts inc lude d in a wa rd

CT U Ro le : Po st a wa rd (se t-up)

 Pro to c o l de ve lo pme nt  Co o rdina te me e ting s o f o ve rsig ht c o mmitte e s  L

ia ise with spo nso r

 Ma na g e me nt o f tria l supplie s  CRF

a nd da ta b a se de ve lo pme nt (E lse vie r MACRO,

• the r)

 T

ria l a ppro va ls – e thic a l, re g ula to ry, institutio na l

 E

sta b lish/ ma inta in E sse ntia l Do c ume nts c e ntra lly

 Site initia tio n a nd o ng o ing c o mmunic a tio n

Re c ruitme nt a nd fo llo w-up

 Prima ry c o nta c t  Sa fe ty mo nito ring / re po rting  Pro g re ss re po rts, a me ndme nt no tific a tio n  Mo nito r a c c rua l  Ong o ing da ta b a se suppo rt, da ta q ue ry re so lutio n  I

nte rim sta tistic a l a na lysis a s pe r a na lysis pla n

 Org a nise a nd pre pa re re po rts fo r o ve rsig ht

c o mmitte e s

 No tific a tio n o f the e nd o f the tria l  Arc hiving a rra ng e me nts

Whe n to invo lve a CT U

 As e a rly a s po ssib le  CT

I MP (usua lly)

 Multi-c e ntre RCT

(CT I MP/ no nCT I MP)

 Multi-c e ntre pilo t/ fe a sib ility  Me tho do lo g y  Hig h risk  Pro po se d funde r  Co sts fo r CT

U a re inc lude d in g ra nt a pplic a tio ns

Invention for Innovation (I4I) funding stream

Steven Lane – RDS NW Adviser and I4I champion

I4I

• Programme supports the pre-clinical and clinical development of

medical devices in areas of existing or emerging patient need.

• De-risk

early stage projects that have a strong potential for commercialisation and acceptance for use in the NHS.

• Must have demonstrated proof of principle – clear pathway towards

adoption and commercialisation.

I4I

• Expected outcome – advanced or clinically validated prototype medical

device, technology or intervention.

• Three funding streams:

Product Development Award (PDA) Connect Award Challenge Award. Two-stage application process.

PDA

• Supports innovation at any stage of the translational research and

development pathway.

• Funding stream is researcher-led does not specify specific topics.
• Must include applicants from two organisation types – NHS trust, HE

institution or Small to Medium enterprise (SME)

• No upper funding limit – up to 3 years duration – Two funding

applications per year.

PDA

What is funded:

• research and development of medical, active implantable and in vitro

diagnostic devices.

• product or technology development required to enable a technology for

clinical use.

• R&D/feasibility studies of techniques or technologies from other industry

sectors that could impact in health care.

• provide data relating to safety and effectiveness of a device.
• health economic relating to real-life implementation of a device.
• training associated with adoption/implementation of a device.

Challenge awards

• Commissioned on an ad hoc basis in areas of existing or emerging health

care need.

• Output –technologies with potential to offer improved outcomes for NHS

patients.

• Aim to shorted evidence gap between safety/efficacy studies new or

nearly CE marked technologies and what is required by commissioners and regulators.

• No upper funding limit.

Challenge awards

What is funded:

• activities associated with the development and delivery evaluation of

innovations in real-world setting.

• health economic evaluation.
• work around business development, market analysis and development of

case for adoption.

• small changes to the technology.
• training associated with the implementation.

Connect award

• Aimed at SMEs in need of a funding boost to reach next stage in

development pathway – apply for further funding PDA.

• De-risk

projects at any stage

• f

the translational research and development pathway to follow-on investment.

• Applications must be from SME.
• £50,000 to £150,000 over 6 to12 month period.

Thank you

End of morning session – Thank you for joining us

Watch two RDS NW clients speak about their experiences next or later at:

• www.rds-nw.nihr.ac.uk/announcements/meet-our-

clients-video-shalom-srirangam

• www.rds-nw.nihr.ac.uk/announcements/meet-our-

clients-videos-professor-simon-rogers